Vivoryon Therapeutics N.V. Presents Topline Phase 2 Data from VIVA-MIND Strongly Supporting Varoglutamstat’s Potential to Improve Kidney Function
December 09, 2024 01:00 ET
|
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Presents Topline Phase 2 Data fromVIVA-MIND Strongly Supporting Varoglutamstat’s Potential toImprove Kidney Function VIVA-MIND Phase 2 data confirm results of...
Lead Real Estate Co., Ltd. Opening New Apartment Hotel, ENT TERRACE GINZA PREMIUM, in Tokyo
December 08, 2024 21:00 ET
|
LEAD REAL ESTATE CO., LTD
TOKYO, Dec. 08, 2024 (GLOBE NEWSWIRE) -- Lead Real Estate Co., Ltd. (Nasdaq: LRE) (“LRE” or “the Company”), a Japanese real estate developer of luxury residential properties including single-family...
Australia's Rangebank Battery Energy Storage System, Victoria's second largest battery, is opened
December 08, 2024 20:06 ET
|
Fluence
MELBOURNE, Australia, Dec. 08, 2024 (GLOBE NEWSWIRE) -- Fluence Energy, Inc. ("Fluence" or the “Company”) (NASDAQ: FLNC), a global market leader delivering intelligent energy storage, operational...
Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis (MF) and Anemia in an Oral Presentation at the 66th American Society of Hematology (ASH) Annual Meeting
December 08, 2024 20:00 ET
|
Disc Medicine Inc
Demonstrated durable hematologic response across all patient subgroups, regardless of baseline transfusion status and concomitant JAK inhibitor therapyPhase 2 study in MF anemia has been initiated,...
Zwischenergebnisse der Monotherapie mit Petosemtamab von Merus zeigen weiterhin klinisch signifikante Aktivität bei 2L+ r/m HNSCC
December 08, 2024 14:12 ET
|
Merus N.V.
Studie mit Petosemtamab in Kombination mit Pembrolizumab bei 1L r/m PD-L1-exprimierendem HNSCC läuft, Aktualisierung der klinischen Daten für 2025 geplant Evaluierung von Petosemtamab bei mCRC auf 1L...
Les données intermédiaires de Merus portant sur le pétosemtamab continuent de démontrer une activité cliniquement significative dans le traitement de 2e ligne et lignes ultérieures du CETC r/m
December 08, 2024 14:12 ET
|
Merus N.V.
Étude du pétosemtamab en association avec le pembrolizumab en 1re ligne de traitement dans le CETC r/m exprimant PD-L1 en cours, avec une actualisation des données cliniques prévue pour 2025 ...
Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting
December 08, 2024 13:45 ET
|
Beam Therapeutics
NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels of Hemoglobin F mAb Dosing...
Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat
December 08, 2024 12:40 ET
|
Agios Pharmaceuticals, Inc.
– ENERGIZE-T Study Achieved Primary and All Key Secondary Endpoints in Adult Patients with Transfusion-Dependent Alpha- or Beta-Thalassemia – – ENERGIZE-T is First Phase 3 Study to Demonstrate...
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader
December 08, 2024 12:30 ET
|
C4 Therapeutics, Inc.
In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36 Percent Overall Response Rate (ORR) and 45 Percent Clinical Benefit Rate (CBR);...
Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
December 08, 2024 12:00 ET
|
Cogent Biosciences, Inc.
52% ORR per mIWG criteria, including 83% ORR for patients receiving 100 mg BID 88% ORR per PPR criteria, including 100% ORR for patients receiving 100 mg BID Median time to response 2.2 months with...